Development of treatment-decision algorithms for children evaluated for pulmonary tuberculosis: an individual participant data meta-analysis.


Journal

The Lancet. Child & adolescent health
ISSN: 2352-4650
Titre abrégé: Lancet Child Adolesc Health
Pays: England
ID NLM: 101712925

Informations de publication

Date de publication:
05 2023
Historique:
received: 10 11 2022
revised: 06 01 2023
accepted: 10 01 2023
medline: 21 4 2023
pubmed: 17 3 2023
entrez: 16 3 2023
Statut: ppublish

Résumé

Many children with pulmonary tuberculosis remain undiagnosed and untreated with related high morbidity and mortality. Recent advances in childhood tuberculosis algorithm development have incorporated prediction modelling, but studies so far have been small and localised, with limited generalisability. We aimed to evaluate the performance of currently used diagnostic algorithms and to use prediction modelling to develop evidence-based algorithms to assist in tuberculosis treatment decision making for children presenting to primary health-care centres. For this meta-analysis, we identified individual participant data from a WHO public call for data on the management of tuberculosis in children and adolescents and referral from childhood tuberculosis experts. We included studies that prospectively recruited consecutive participants younger than 10 years attending health-care centres in countries with a high tuberculosis incidence for clinical evaluation of pulmonary tuberculosis. We collated individual participant data including clinical, bacteriological, and radiological information and a standardised reference classification of pulmonary tuberculosis. Using this dataset, we first retrospectively evaluated the performance of several existing treatment-decision algorithms. We then used the data to develop two multivariable prediction models that included features used in clinical evaluation of pulmonary tuberculosis-one with chest x-ray features and one without-and we investigated each model's generalisability using internal-external cross-validation. The parameter coefficient estimates of the two models were scaled into two scoring systems to classify tuberculosis with a prespecified sensitivity target. The two scoring systems were used to develop two pragmatic, treatment-decision algorithms for use in primary health-care settings. Of 4718 children from 13 studies from 12 countries, 1811 (38·4%) were classified as having pulmonary tuberculosis: 541 (29·9%) bacteriologically confirmed and 1270 (70·1%) unconfirmed. Existing treatment-decision algorithms had highly variable diagnostic performance. The scoring system derived from the prediction model that included clinical features and features from chest x-ray had a combined sensitivity of 0·86 [95% CI 0·68-0·94] and specificity of 0·37 [0·15-0·66] against a composite reference standard. The scoring system derived from the model that included only clinical features had a combined sensitivity of 0·84 [95% CI 0·66-0·93] and specificity of 0·30 [0·13-0·56] against a composite reference standard. The scoring system from each model was placed after triage steps, including assessment of illness acuity and risk of poor tuberculosis-related outcomes, to develop treatment-decision algorithms. We adopted an evidence-based approach to develop pragmatic algorithms to guide tuberculosis treatment decisions in children, irrespective of the resources locally available. This approach will empower health workers in primary health-care settings with high tuberculosis incidence and limited resources to initiate tuberculosis treatment in children to improve access to care and reduce tuberculosis-related mortality. These algorithms have been included in the operational handbook accompanying the latest WHO guidelines on the management of tuberculosis in children and adolescents. Future prospective evaluation of algorithms, including those developed in this work, is necessary to investigate clinical performance. WHO, US National Institutes of Health.

Sections du résumé

BACKGROUND
Many children with pulmonary tuberculosis remain undiagnosed and untreated with related high morbidity and mortality. Recent advances in childhood tuberculosis algorithm development have incorporated prediction modelling, but studies so far have been small and localised, with limited generalisability. We aimed to evaluate the performance of currently used diagnostic algorithms and to use prediction modelling to develop evidence-based algorithms to assist in tuberculosis treatment decision making for children presenting to primary health-care centres.
METHODS
For this meta-analysis, we identified individual participant data from a WHO public call for data on the management of tuberculosis in children and adolescents and referral from childhood tuberculosis experts. We included studies that prospectively recruited consecutive participants younger than 10 years attending health-care centres in countries with a high tuberculosis incidence for clinical evaluation of pulmonary tuberculosis. We collated individual participant data including clinical, bacteriological, and radiological information and a standardised reference classification of pulmonary tuberculosis. Using this dataset, we first retrospectively evaluated the performance of several existing treatment-decision algorithms. We then used the data to develop two multivariable prediction models that included features used in clinical evaluation of pulmonary tuberculosis-one with chest x-ray features and one without-and we investigated each model's generalisability using internal-external cross-validation. The parameter coefficient estimates of the two models were scaled into two scoring systems to classify tuberculosis with a prespecified sensitivity target. The two scoring systems were used to develop two pragmatic, treatment-decision algorithms for use in primary health-care settings.
FINDINGS
Of 4718 children from 13 studies from 12 countries, 1811 (38·4%) were classified as having pulmonary tuberculosis: 541 (29·9%) bacteriologically confirmed and 1270 (70·1%) unconfirmed. Existing treatment-decision algorithms had highly variable diagnostic performance. The scoring system derived from the prediction model that included clinical features and features from chest x-ray had a combined sensitivity of 0·86 [95% CI 0·68-0·94] and specificity of 0·37 [0·15-0·66] against a composite reference standard. The scoring system derived from the model that included only clinical features had a combined sensitivity of 0·84 [95% CI 0·66-0·93] and specificity of 0·30 [0·13-0·56] against a composite reference standard. The scoring system from each model was placed after triage steps, including assessment of illness acuity and risk of poor tuberculosis-related outcomes, to develop treatment-decision algorithms.
INTERPRETATION
We adopted an evidence-based approach to develop pragmatic algorithms to guide tuberculosis treatment decisions in children, irrespective of the resources locally available. This approach will empower health workers in primary health-care settings with high tuberculosis incidence and limited resources to initiate tuberculosis treatment in children to improve access to care and reduce tuberculosis-related mortality. These algorithms have been included in the operational handbook accompanying the latest WHO guidelines on the management of tuberculosis in children and adolescents. Future prospective evaluation of algorithms, including those developed in this work, is necessary to investigate clinical performance.
FUNDING
WHO, US National Institutes of Health.

Identifiants

pubmed: 36924781
pii: S2352-4642(23)00004-4
doi: 10.1016/S2352-4642(23)00004-4
pmc: PMC10127218
pii:
doi:

Types de publication

Meta-Analysis Journal Article Research Support, U.S. Gov't, P.H.S. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

336-346

Subventions

Organisme : NIGMS NIH HHS
ID : T32 GM007205
Pays : United States
Organisme : NICHD NIH HHS
ID : K23 HD072802
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD058971
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI137093
Pays : United States
Organisme : Medical Research Council
ID : MR/R007942/1
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : R01 AI147854
Pays : United States
Organisme : NICHD NIH HHS
ID : F30 HD105440
Pays : United States
Organisme : NIAID NIH HHS
ID : K23 AI143479
Pays : United States
Organisme : PEPFAR
Pays : United States
Organisme : FIC NIH HHS
ID : K43 TW011028
Pays : United States
Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

© 2023 World Health Organization. Published by Elsevier Ltd. All rights reserved. This is an Open Access article published under the CC BY 3.0 IGO license which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any use of this article, there should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.

Déclaration de conflit d'intérêts

Declaration of interests We declare no competing interests.

Références

J Pediatric Infect Dis Soc. 2022 Mar 24;11(3):108-114
pubmed: 34902033
N Engl J Med. 2022 Mar 10;386(10):911-922
pubmed: 35263517
BMC Public Health. 2019 Apr 29;19(1):446
pubmed: 31035984
Stat Methods Med Res. 2019 Sep;28(9):2768-2786
pubmed: 30032705
Pediatrics. 2019 Sep;144(3):
pubmed: 31455612
Confl Health. 2020 May 14;14:26
pubmed: 32467723
Lancet Glob Health. 2017 Sep;5(9):e898-e906
pubmed: 28807188
Lancet Child Adolesc Health. 2022 Feb;6(2):106-115
pubmed: 34800370
J Clin Epidemiol. 2005 Oct;58(10):982-90
pubmed: 16168343
Clin Infect Dis. 2015 Oct 15;61Suppl 3:S179-87
pubmed: 26409281
Lancet Respir Med. 2015 Jun;3(6):451-61
pubmed: 25812968
Pathogens. 2021 Dec 01;10(12):
pubmed: 34959523
Int J Tuberc Lung Dis. 1998 Feb;2(2):116-23
pubmed: 9562121
Open Forum Infect Dis. 2021 Feb 18;8(3):ofab075
pubmed: 33738322
Trop Med Int Health. 2009 Nov;14(11):1329-37
pubmed: 19735381
BMJ. 2015 Jan 07;350:g7594
pubmed: 25569120
J Infect Dis. 2017 Nov 6;216(suppl_7):S702-S713
pubmed: 29117342
Int J Tuberc Lung Dis. 2018 Nov 1;22(11):1314-1321
pubmed: 30355411
Clin Infect Dis. 2021 Aug 16;73(4):e904-e912
pubmed: 33449999

Auteurs

Kenneth S Gunasekera (KS)

Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA. Electronic address: kenneth.gunasekera@yale.edu.

Olivier Marcy (O)

Inserm UMR1219, Institut de Recherche pour le Développement EMR 271, GHiGS, University of Bordeaux, Bordeaux, France.

Johanna Muñoz (J)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.

Elisa Lopez-Varela (E)

ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain; Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique; Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.

Moorine P Sekadde (MP)

National Tuberculosis and Leprosy Program, Kampala, Uganda.

Molly F Franke (MF)

Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.

Maryline Bonnet (M)

University of Montpellier, TransVIHMI, Institut de Recherche pour le Développement, Inserm, Montpellier, France; Epicentre, Mbarara, Uganda.

Shakil Ahmed (S)

Department of Paediatrics, Dhaka Medical College Hospital, Dhaka, Bangladesh.

Farhana Amanullah (F)

Indus Hospital & Health Network, Karachi, Pakistan; The Aga Khan University Hospital, Karachi, Pakistan.

Aliya Anwar (A)

Indus Hospital & Health Network, Karachi, Pakistan.

Orvalho Augusto (O)

Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique.

Rafaela Baroni Aurilio (RB)

Instituto de Puericultura e Pediatria Martagao Gesteira, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

Sayera Banu (S)

Programme on Emerging Infections, Infectious Disease Division, icddr,b, Dhaka, Bangladesh.

Iraj Batool (I)

Indus Hospital & Health Network, Karachi, Pakistan.

Annemieke Brands (A)

Global Tuberculosis Programme, WHO, Geneva, Switzerland.

Kevin P Cain (KP)

US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Lucía Carratalá-Castro (L)

ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain; Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique.

Maxine Caws (M)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK; Birat Nepal Medical Trust, Lazmipat, Kathmandu, Nepal.

Eleanor S Click (ES)

US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Lisa M Cranmer (LM)

Department of Pediatrics, Emory School of Medicine, Atlanta, GA, USA; Department of Epidemiology, Emory Rollins School of Public Health, Atlanta, GA, USA; Children's Healthcare of Atlanta, Atlanta, GA, USA.

Alberto L García-Basteiro (AL)

ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain; Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Barcelona, Spain.

Anneke C Hesseling (AC)

Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.

Julie Huynh (J)

Oxford University Clinical Research Unit, Centre for Tropical Diseases, Ho Chi Minh City, Viet Nam; Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.

Senjuti Kabir (S)

Programme on Emerging Infections, Infectious Disease Division, icddr,b, Dhaka, Bangladesh.

Leonid Lecca (L)

Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA; Socios En Salud Surcursal Perú, Lima, Perú.

Anna Mandalakas (A)

Global TB Program, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA; Clinical Infectious Disease Group, German Center for Infectious Research, Clinical TB Unit, Research Center Borstel, Borstel, Germany.

Farai Mavhunga (F)

Global Tuberculosis Programme, WHO, Geneva, Switzerland.

Aye Aye Myint (AA)

Department of Paediatrics, University of Medicine, Mandalay, Myanmar.

Kyaw Myo (K)

Department of Paediatrics, University of Medicine, Magway, Myanmar.

Dorah Nampijja (D)

Department of Paediatrics, Mbarara University of Science and Technology, Mbarara, Uganda.

Mark P Nicol (MP)

Division of Infection and Immunity, Department of Biomedical Sciences, University of Western Australia, Perth, WA, Australia.

Patrick Orikiriza (P)

Epicentre, Mbarara, Uganda; Department of Microbiology, Division of Basic Medical Sciences, School of Medicine, University of Global Health Equity, Kigali, Rwanda.

Megan Palmer (M)

Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.

Clemax Couto Sant'Anna (CC)

Faculty of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

Sara Ahmed Siddiqui (SA)

Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA; Indus Hospital & Health Network, Karachi, Pakistan.

Jonathan P Smith (JP)

Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA; US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Rinn Song (R)

Department of Pediatrics, Harvard Medical School, Boston, MA, USA; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.

Nguyen Thuy Thuong Thuong (NT)

Oxford University Clinical Research Unit, Centre for Tropical Diseases, Ho Chi Minh City, Viet Nam; Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.

Vibol Ung (V)

University of Health Sciences, Phnom Penh, Cambodia; National Pediatric Hospital, Phnom Penh, Cambodia.

Marieke M van der Zalm (MM)

Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.

Sabine Verkuijl (S)

Global Tuberculosis Programme, WHO, Geneva, Switzerland.

Kerri Viney (K)

Global Tuberculosis Programme, WHO, Geneva, Switzerland; School of Public Health, University of Sydney, Sydney, NSW, Australia.

Elisabetta G Walters (EG)

Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa; Directorate of Integrated Laboratory Medicine, Institute of Human Genetics, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK.

Joshua L Warren (JL)

Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA.

Heather J Zar (HJ)

Department of Paediatrics and Child Health, Red Cross Children's Hospital, and SA-MRC Unit on Child and Adolescent Health, University of Cape Town, Cape Town, South Africa.

Ben J Marais (BJ)

The Children's Hospital at Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.

Stephen M Graham (SM)

Department of Paediatrics and Murdoch Children's Research Institute, Royal Children's Hospital, University of Melbourne, Melbourne, VIC, Australia; Burnet Institute, Melbourne, VIC, Australia.

Thomas P A Debray (TPA)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.

Ted Cohen (T)

Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.

James A Seddon (JA)

Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa; Department of Infectious Diseases, Imperial College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH